News & Updates

Apremilast fails to deliver clinical benefits in active ankylosing spondylitis

29 Aug 2021

Use of apremilast does not provide any clinical benefit in patients with active ankylosing spondylitis (AS), but the safety and tolerability of this treatment are consistent with its known profile, reports a study.

Apremilast fails to deliver clinical benefits in active ankylosing spondylitis

29 Aug 2021

Secukinumab improves enthesitis in patients with ankylosing spondylitis

28 Aug 2021

In patients with ankylosing spondylitis (AS), treatment with secukinumab leads to improvement in enthesitis at overall Maastricht AS Enthesitis Score (MASES) and axial sites, results of a recent study have shown.

Secukinumab improves enthesitis in patients with ankylosing spondylitis

28 Aug 2021

Secondhand smoking exposure in childhood poses risk of adult-onset RA

26 Aug 2021

Children whose parents smoke are likely to develop seropositive rheumatoid arthritis (RA) as adults, regardless of their smoking habits, a study suggests.

Secondhand smoking exposure in childhood poses risk of adult-onset RA

26 Aug 2021

RA-related factors may contribute to higher TB risk

25 Aug 2021 by

Some factors associated with rheumatoid arthritis (RA), such as treatment with leflunomide, azathioprine, and prednisolone and concomitant obstructive lung disease, can elevate the risk of tuberculosis (TB) in biologic-naïve patients with RA, reveals a study.

RA-related factors may contribute to higher TB risk

25 Aug 2021

Ixekizumab for axSpA patients in remission: To continue or not?

24 Aug 2021 by

For individuals with axial spondyloarthritis (axSpA) who have achieved remission following treatment with ixekizumab, continuing the drug led to better outcomes than withdrawal, suggests findings from the randomized withdrawal-retreatment period (RWRP) of the ongoing phase III COAST-Y trial.

Ixekizumab for axSpA patients in remission: To continue or not?

24 Aug 2021

CREDO 1: Novel biologic for rheumatoid arthritis hits mark

19 Aug 2021 by

Treatment with olokizumab yields significant improvements in signs and symptoms of rheumatoid arthritis (RA), particularly among patients with active disease despite receipt of an adequate dose of methotrexate, according to the results of the phase III CREDO 1 trial.

CREDO 1: Novel biologic for rheumatoid arthritis hits mark

19 Aug 2021

Inflammatory arthritis can hurt male fertility

15 Aug 2021

Men diagnosed with inflammatory arthritis prior to and during the peak of reproductive age appear to have impaired fertility, with most being childless and having fertility problems, according to data from the iFAME-Fertility study.

Inflammatory arthritis can hurt male fertility

15 Aug 2021

Fibromyalgia patients also show increased sensitivity to mild stimuli

14 Aug 2021

The hypersensitivity of patients with fibromyalgia does not appear to be limited to painful stimuli but also to other stimuli such as sound, as reported in a study.

Fibromyalgia patients also show increased sensitivity to mild stimuli

14 Aug 2021

Exercise capacity low in AxSpA, translates to increased long-term CV risk

10 Aug 2021

Patients with axial spondyloarthritis (AxSpA) appear to have markedly low exercise capacity, which contributes to heightened 10-year cardiovascular (CV) event risk in this population, a study reports.

Exercise capacity low in AxSpA, translates to increased long-term CV risk

10 Aug 2021

Riociguat delays worsening of sarcoidosis-associated pulmonary hypertension

09 Aug 2021

Treatment with riociguat helps prevent clinical worsening and improve exercise capacity in patients with sarcoidosis-associated pulmonary hypertension (SAPH), according to the results of a trial.

Riociguat delays worsening of sarcoidosis-associated pulmonary hypertension

09 Aug 2021

News & Updates

Filter by Specialty:

Specialty:

Apremilast fails to deliver clinical benefits in active ankylosing spondylitis

Apremilast fails to deliver clinical benefits in active ankylosing spondylitis

Secukinumab improves enthesitis in patients with ankylosing spondylitis

Secukinumab improves enthesitis in patients with ankylosing spondylitis

Secondhand smoking exposure in childhood poses risk of adult-onset RA

Secondhand smoking exposure in childhood poses risk of adult-onset RA

RA-related factors may contribute to higher TB risk

RA-related factors may contribute to higher TB risk

Ixekizumab for axSpA patients in remission: To continue or not?

Ixekizumab for axSpA patients in remission: To continue or not?

CREDO 1: Novel biologic for rheumatoid arthritis hits mark

CREDO 1: Novel biologic for rheumatoid arthritis hits mark

Inflammatory arthritis can hurt male fertility

Inflammatory arthritis can hurt male fertility

Fibromyalgia patients also show increased sensitivity to mild stimuli

Fibromyalgia patients also show increased sensitivity to mild stimuli

Exercise capacity low in AxSpA, translates to increased long-term CV risk

Exercise capacity low in AxSpA, translates to increased long-term CV risk

Riociguat delays worsening of sarcoidosis-associated pulmonary hypertension

Riociguat delays worsening of sarcoidosis-associated pulmonary hypertension